Primary Use

Prevention of Acute Respiratory Infections. The primary use of CVT-E002/COLD-fX as documented by published clinical trials is for the prevention of acute respiratory infections (ARI). The claim for the product approved by the Canadian government is “helps reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system.”13 In studies with adult populations, including the elderly, COLD-fX has been shown to reduce the incidence of ARI when used preventively during the cold and flu season.14,15,16